Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patient...
Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy
Using the novel antibody-drug conjugate, loncastuximab tesirine to treat patients with R/R diffuse large B-cell lymphoma ( Prof Carmelo Carlo-Stella - Humanitas Cancer Center, Milan, Italy )
26 Jun 2020
Treating patients with multiple myeloma in the real world
Dr Ajai Chari and Prof Roman Hájek
Treating patients with multiple myeloma in the real world ( Dr Ajai Chari and Prof Roman Hájek )
26 Jun 2020
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine...
Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy
ASCEND final results: Acalabrutinib vs idelalisib plus rituximab or bendamustine plus rituximab in R/R CLL ( Prof Paolo Ghia - Vita-Salute San Raffaele University, Milan, Italy )
26 Jun 2020
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma
Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain
KarMMa: Idecabtagene vicleucel in patients with r/r multiple myeloma ( Prof Jesús San Miguel - Universidad de Navarra, Pamplona, Spain )
26 Jun 2020
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients w...
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA
Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML ( Dr Naval Daver - MD Anderson Cancer Center, Houston, USA )
26 Jun 2020
New CAR T therapy for relapsed and refractory ALL
Dr Claire Roddie - University College London, London, UK
New CAR T therapy for relapsed and refractory ALL ( Dr Claire Roddie - University College London, London, UK )
25 Jun 2020
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma
Prof Philippe Moreau - University of Nantes, Nantes, France
IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma ( Prof Philippe Moreau - University of Nantes, Nantes, France )
25 Jun 2020
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythe...
Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy
LOW-PV interim analysis: Ropeginterferon versus phlebotomy in low-risk polycythemia vera ( Prof Tiziano Barbui - FROM Research Foundation, Bergamo, Italy )
25 Jun 2020
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexame...
Prof Efstathios Kastritis - University of Athens, Athens, Greece
ANDROMEDA: Subcutaneous daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly-diagnosed AL amyloidosis ( Prof Efstathios Kastritis - University of Athens, Athens, Greece )
25 Jun 2020
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer
Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany
ASCO 2020: Updates in non-metastatic castration-resistant prostate cancer ( Prof Boris Hadaschik - University of Duisburg-Essen, Essen, Germany )
24 Jun 2020
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blina...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
The NEUF study: Treatment of r/r Philadelphia chromosome-positive ALL with blinatumomab ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymp...
Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain
BLIN-01: Blinatumomab for high-risk, Philadelphia chromosome-negative acute lymphoblastic leukaemia ( Dr Josep Ribera - Catalan Institute of Oncology, Barcelona, Spain )
23 Jun 2020